Statement re. Suspension

 Tissue Regenix Group plc

('Tissue Regenix', the 'Company')

Statement re. Suspension

Tissue Regenix plc (AIM: TRX), the regenerative medical devices company, announces that it has requested the temporary suspension of trading on AIM of the Company's ordinary shares, which has taken place with immediate effect.

The temporary suspension will allow the new Senior Leadership Team to further consider the previously announced restatement of revenue numbers for the financial year ended 31 December 2024 ("FY24"), the impact this has on H125 adjusted EBITDA, and the cash-position and ongoing expected performance of the business. Until this further review takes place the Company is not in a position to clarify its financial position.

Strict financial controls are being implemented, and a comprehensive review of the Group's cost structure is already underway, targeting a $2m+ cost reduction.

The Board remain committed to ensuring the recovery of the business and delivering sustainable, long-term earnings growth for shareholders. Further announcements will be made in due course.

For more information:

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation 'MAR' EU no. 596/2014. Upon the publication of this announcement via the Regulatory Information Service 'RIS', this inside information is now considered to be in the public domain.

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.